Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 5, 2025Clinical pharmacology and therapyOpen Access

АА-amyloidosis: etiology, clinical features and efficacy of interleukin-6 inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

PNP. NovikovVRV. RameevNBN. Bulanov

Discussion

Loading...

Member takes

Overview

Case report highlights IL-6 inhibitors' potential in treating AA-amyloidosis in rheumatoid arthritis, suggesting efficacy.

Key Points

  • IL-6 inhibitors may retard AA-amyloidosis progression in rheumatoid arthritis patients, supporting anti-inflammatory roles.
  • Case study illustrates that rheumatoid arthritis is a common cause of AA-amyloidosis and highlights treatment approaches.
  • AA-amyloidosis typically manifests as isolated kidney disease, differing from other amyloidosis types like AL or ATTR.
  • Effective therapies for rheumatoid arthritis have reduced the incidence of AA-amyloidosis in recent years, highlighting treatment importance.

Cite This Study

Novikov et al. (2025) studied this question.

synapsesocial.com/papers/68e24e60d6d66a53c247349ehttps://doi.org/10.32756/0869-5490-2025-3-55-64
View Full Paper
Ask AI
Bookmark
Share